Kyowa Kirin Co., Ltd. announced that CRYSVITA® (burosumab) has been approved for the option of self-administration in the European Union (EU) for the treatment of X-linked hypophosphataemia (XLH), a rare metabolic bone disease that impacts children and adults. The approval means that some patients or carers may be suitable to administer CRYSVITA themselves, at the recommendation of the treating physician, in its licensed indication for the treatment of XLH in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. CRYSVITA is administered by subcutaneous injection.2 CRYSVITA treatment will still need to be initiated by a physician experienced in the management of patients with metabolic bone diseases. Subsequently, if the patient is receiving a stable dose, the physician may recommend that administration can be performed by the patient or carer following appropriate training. The first self-administered dose after drug initiation or dose change will need to be conducted under the supervision of a healthcare professional. X-linked hypophosphataemia (XLH) is a rare, genetic disease that causes abnormalities in the bones, muscles, and joints. XLH is not life-threatening, but its burden is life-long and progressive, and it may reduce a person’s quality of life. People with XLH have a genetic defect on the X-chromosome, which causes an excessive loss of phosphate through the urine and poor absorption from the gut, resulting in chronically low levels of phosphate in the blood. Phosphate is a key mineral needed for maintaining the body’s energy levels, muscle function, and the formation of healthy bones and teeth. While there is no cure for XLH, therapies aimed at helping to restore phosphate to normal levels within the body may help to improve the symptoms of the disease. XLH is the most common form of hereditary rickets. It can sometimes appear in individuals with no family history of the disease but is usually passed down from a parent who carries the defective gene.